{"name":"Kidney Cancer Research Bureau","slug":"kidney-cancer-research-bureau","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GM-CSF, IFN alpha and IL-2","genericName":"GM-CSF, IFN alpha and IL-2","slug":"gm-csf-ifn-alpha-and-il-2","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"GM-CSF, IFN alpha and IL-2","genericName":"GM-CSF, IFN alpha and IL-2","slug":"gm-csf-ifn-alpha-and-il-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUm13cGVzZF9rZnZSbkh2MGVjSGwwU3hGOXN6X0FvRkFQeDgtR0lkZjYxd3lhcUF4ck1ZcDhsQmV2OGY2NDViaHhNTXpmY20zQzBFZXpwRk5GVE1HZU1BY01GSEJPSTgwUmlobnNyUGVIVDNtbk8zR1g2amJjZ2ZsZjhNVTZOTUNnZjdPWmJpVXZETTJETVJlUkptTmxTVzNpU0kxWS11OS0?oc=5","date":"2026-02-28","type":"pipeline","source":"Fierce Pharma","summary":"A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer - Fierce Pharma","headline":"A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNYldVdldrSmh0VXNydDVnakNXMnM5RkhjS3ZrV2Z5OEJBVUpsZzFhaVVMODJWai1RTFlZMktienFTSWNEOWhpNzd1alJ6c0pxR3o5UmxpVEVKeEtWemhyZTh4TktEOWl0OVA0cDV3OXlFdm1ZTUh2VGw3ZTRBdFFBbzY1YXotUUV4ZjRGNWptWmc?oc=5","date":"2025-10-09","type":"pipeline","source":"healthbusiness.co.ke","summary":"Kenya’s Pharmacy Board Flags Fake Avastin Cancer Drug - healthbusiness.co.ke","headline":"Kenya’s Pharmacy Board Flags Fake Avastin Cancer Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNYkpqSXhvQWNwdGU2Vkl0dDN6WkNRMXcxNW5ZcGlZXzZsT2RkSFhtNUF3SHpab2JSNW1hUXd6dWU0Y0hsWUZGV3dIc2hwOEN4Q1dBc1VZWkVpZy14SE9BWG42bVUxVzloZE1RcWloakRIVHRJMFI4eThvZkpEQTVMVkMtNUNWZnBvNGdpVHpoVWNZQndodlpmOGVkaTJ2T3dKVGFIRW5nQXZuR0Vzc3RYekY4QmtneEVOdlZn?oc=5","date":"2025-09-17","type":"pipeline","source":"ASCO Daily News","summary":"Selecting First-Line TKI Monotherapy for Metastatic Renal Cell Carcinoma: The Balance of Efficacy and Toxicity and the Role of IMDC Risk - ASCO Daily News","headline":"Selecting First-Line TKI Monotherapy for Metastatic Renal Cell Carcinoma: The Balance of Efficacy and Toxicity and the R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNUTdRZFVEYkh5WFgzeklCSVVPNkxlYmpZaDF1cmZibTB1WWlib2tnNm9lSjRySkVadno3Vy1SeTJOcF9zYjIxRjZlbkFlMFEzZEp5MHNBVWtZcUJRVEl6Sm8tcmxZWlhqVUpSYUZ5aEQ2cFJYMTdGYnhmWDhzSEotNzk3aw?oc=5","date":"2025-07-03","type":"pipeline","source":"pharmaphorum","summary":"Women who changed cancer research: A timeline - pharmaphorum","headline":"Women who changed cancer research: A timeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOdWFuZjU3VUtaWXpySk1mdTZ3UGJVUGFRWjBEckh4SktXTC1NUUFlQ0pZTHFCS3h5QWhOcG5xc0U3UlEwS1I2aDdNN0ZsMmZyamRCejFsQVBwenBFQ0IwalNWTGZ0QjBnek53Q24zSVYwd1FxcVoybmpQSnVDUU52V255Q1lCcV92?oc=5","date":"2025-02-19","type":"regulatory","source":"National Cancer Institute (.gov)","summary":"FDA Approves Opdivo Qvantig - National Cancer Institute (.gov)","headline":"FDA Approves Opdivo Qvantig - National Cancer Institute (.gov)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOOUtQWHFBZ3pja1RNWUJBQ2ltLWFPLTczN1dzWHRqQ1BSOHpfUVFiWmZ1MGxzaUktVURYUnpfXy1vMjl2NEp1OEFybzE5RzF1R01XdWNOdTlsOGtmUnhURlZSSlBGVGxtZXYtVDl4NFdzZGVfOE80X2dudzRXMXp6OHM3Wk1QbmRsYW9aYXRxMVVLMjVxekg2ZEdTcUZOelFLRmNqLXJ3?oc=5","date":"2024-09-25","type":"pipeline","source":"Boehringer Ingelheim","summary":"Boehringer expands cancer research at Vienna site - Boehringer Ingelheim","headline":"Boehringer expands cancer research at Vienna site","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQU0NTNkNqcS14R1d4TTl6UllMek9MSVhlZTdRVzQxTkZqanUwRVpHMFZrNkYtM01mYzF5NW9EM3RuSzZUaHNxYld2QVVrcUZJbzJKdTlsZmNEdUMzRFdEbkxjTlBybmdza2NBR3B1dHFEeHMzWjd5bG14TmkybkEycnpaZ0VJLS0wZjFfLVdwczQ4Y3ItcUl4dmF1SnNIRG95ckRJZFZmRjItejBaT1B4M2dlNUt1M08tYVBiRlI3LW9ZdDZscWhMaVNaMkFhaWpVZW8zYU1kWlNIUDdSYUpjVG5fNVQ0TU0?oc=5","date":"2024-08-05","type":"regulatory","source":"Radiology Business","summary":"FDA denies pharma firm’s initial application for new kidney cancer imaging agent - Radiology Business","headline":"FDA denies pharma firm’s initial application for new kidney cancer imaging agent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE92SGpRY2RCOUg2ZEJfWHVWb1dhT3hoZkNuRHkzQ2otaWRINEM1WVl0WjBka0syOVRlTlBEd2Ffc0tqbEFDSmNjOEJod04xOV9lTjFiRnZmcXZJMy1jNWcw?oc=5","date":"2024-01-03","type":"regulatory","source":"Nature","summary":"Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis | Scientific Reports - Nature","headline":"Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis | Scientific Reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTTRHbjRTQ01QSTZMcER0ZmoyZktSMldyaG1GeDc5VzhLTXM3UVZiOWVrVWpmbFJLWHpKeWxDU004T1hzX3pDY1MyOGhRdHRDc3BSTkE2YjVXX0hvWUJDeTNJV1ZoRHFkVUZfZVo0ekRwTEUwdXhscWRyUXhlMjktN1B0WnVQbkp3RGMtUzU3V1htTFNhR3ZZWWg2Z2RtaDJ1NHc3bGZWQlpSVEx0ZThHOWRBaFYwVU9tanJMa3pBSXY2cnBtc3h5OS1QZmtYbFR4c3dLOGQ1UQ?oc=5","date":"2023-07-10","type":"trial","source":"The ASCO Post","summary":"CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer - The ASCO Post","headline":"CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPRnZxSVRPOFRwem1KWlVsYThCNFhCQVJ5bWUxUmR2T21QQmtVak9IQjl1LXA2cGNwR2pYQVNFdGthd09Eb1RLWUlodXhOVmpWcHJGUUx3MkZDRm9sMGNDSjQxd3Y5T09DZERHUWhvQlk4dDN2WkFOdXFiVmpITG80V2swZUxUNnhFcFltTzktTVUxMThzYW1KSHpzUlEyeXVEbDgtRVNTU1lCcFNST2pKT1VR?oc=5","date":"2019-02-16","type":"pipeline","source":"BioPharma Dive","summary":"Hunt for immunotherapy combinations turns up success in kidney cancer - BioPharma Dive","headline":"Hunt for immunotherapy combinations turns up success in kidney cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBOVHBVTGRxd0JkUThHSjBrQzEtM3JoT0RDTUFDUkc1bkF2YWI1X3JKUy1oZzlFS3FnamF3bGlycDVLS0FEMk5WOWNYa0Yzenh2M2lPUFF4akJ6M01WSklJ?oc=5","date":"2018-04-05","type":"pipeline","source":"NEJM","summary":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma - NEJM","headline":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNFBlQUVVUXJmVU1LaW5XeXVUVGxnWFdNUE1wY3BQZHRPRk9XZ0tmS0pLQ09jR2VXUk0zcDFiNzc4YTNMS0g5MURjRmJnY015czZnVENaV2RKNEphRXBtTFhZVDEzRk5rWlVOTDRWN2ZWaHd1M1ZWREVwdTlvb0ZVY2JmY2RralBGWnY0?oc=5","date":"2017-08-28","type":"pipeline","source":"Fierce Biotech","summary":"Aveo's phoenix drug tivozanib rises up in Europe - Fierce Biotech","headline":"Aveo's phoenix drug tivozanib rises up in Europe","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}